Zoetis INFORCE 3® Respiratory Vaccine

Zoetis Services LLC

Available Inventory: 0

$62.99
Unit price per

Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Vaccine (Modified-Live Virus)

For beef cattle producers respiratory disease can challenge young calves, and even the cow herd. INFORCE 3^®, an intranasal respiratory vaccine, the market leader since 2015,¹ is for the vaccination of healthy cattle, including pregnant cows, to help protect against respiratory disease caused by bovine respiratory syncytial virus (BRSV), infectious bovine rhinotracheitis (IBR) virus and parainfluenza 3 (PI₃) virus.

Indications: Helps protect against respiratory disease caused by BRSV, IBR and PI₃.

Available as: Vials

For use with: Beef, Dairy

How it Works

As an intranasal respiratory vaccine, INFORCE 3^® causes a local immune response with viral antibodies produced in the nasal passage where BRSV, IBR and PI₃ are most likely to enter the animal’s system.

INFORCE 3^® was the first commercially available intranasal respiratory vaccine that helps protect against respiratory disease caused by BRSV, while also protecting against IBR and PI₃, to help get cattle off to a healthier, more productive start.

INFORCE 3 has seen continued improvements since approval in 2010, including a six-month duration of immunity claim for IBR protection, and a single-nostril administration claim. Additional research also demonstrated no maternal antibody interference for IBR and BRSV.^2,3

Safe for all ages, types and classes of cattle

INFORCE 3^® is safe for use in all types, ages and classes of cattle. INFORCE 3 was demonstrated safe for use in very young calves; high-stress calves; weaned and high-stress stocker calves; recently calved cows; and pregnant heifers and cows.

The Science Behind Effective Control
- Intranasal administration works with the animal's immune system for fast, effective response
- Helps prime the immune system for a memory response to subsequent vaccinations as well as disease challenges
- Contains proprietary, temperature-sensitive IBR and PI₃ strains that replicate most effectively in the upper respiratory tract
- Stimulates safe interferon release for protection
- Helps deliver a healthy start for young beef calves
- Provides at least six months of protection against respiratory disease caused by IBR and at least 57 days of protection against respiratory disease caused by BRSV after single-nostril administration
How Effective Is It?
Proven Respiratory Disease Protection
- All calves vaccinated with INFORCE 3^® survived a severe BRSV challenge in which all unvaccinated controls died.^4,5
- North Dakota research demonstrated that vaccination with INFORCE 3 at birth improved immune response when boosted at pre-weaning with a combination respiratory vaccine (BOVI-SHIELD GOLD ONE SHOT^®).⁶
- INFORCE 3 was shown to help prevent respiratory disease caused by IBR and PI₃, and reduce level and duration of viral shedding caused by IBR and PI₃.^7-9
- INFORCE 3 can be used in beef herds in calves as young as 3 days old, calves at branding, preconditioning or weaning, as well as at pre-shipment, or on arrival in stocker or feedlot operations.
Dosage and Administration
Directions

Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, mix well and administer 2 mL intranasally using a cannula. Place the 2-mL dose into a single nostril or 1-mL dose in each nostril.

Calves vaccinated before the age of 6 months should be revaccinated after 6 months of age to avoid possible maternal antibody interference with immunization. The presence of maternal antibody is known to interfere with the development of active immunity in cattle, and additional boosters will be required in most young animals. Annual revaccination with a single dose is recommended. For further advice on revaccination frequency, consult your veterinarian.

PRECAUTIONS

Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
Use entire contents when first opened.
Sterilized syringes should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
Inactivate unused contents before disposal.
Do not vaccinate within 21 days before slaughter.
Contains gentamicin as preservative.
Fetal health risks associated with the vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined during clinical trials conducted for licensure. Appropriate strategies to address the risks associated with modified live vaccine use in pregnant animals should be discussed with a veterinarian.
As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
Do not mix with other products, except as specified above.
In case of human exposure, contact a physician.

¹ Animalytics data, 2015 to May 2021.
² Mahan SM, Sobecki B, Johnson J, et al. Efficacy of Intranasal Vaccination With a Multivalent Vaccine Containing Temperature-Sensitive Modified-Live Bovine Herpesvirus Type 1 for Protection of Seronegative and Seropositive Calves Against Respiratory Disease. J Am Vet Med Assoc. 2016;248(11):1280-1286.
³ Ellis JA, Gow SP, Mahan S, Leyh R. Duration of Immunity to Experimental Infection With Bovine Respiratory Syncytial Virus Following Intranasal Vaccination of Young Passively Immune Calves. J Am Vet Med Assoc. 2013;243(11):1602-1608.
⁴ Data on file, Study Report No. 3131R-60-08-557, Zoetis Inc.
⁵ Data on file, Study Report No. 3131R-60-09-669, Zoetis Inc.
⁶ Stokka GL, Neville B, Seeger JT, Stoltenow C, Dyer N, Gaspers JJ. Evaluation of the serologic effect of concurrent IBR, BRSV, PI3 and Mannheimia vaccination and time interval between the first and second dose on the subsequent serological response to the Mannheimia toxoid and BRSV fractions on spring-born beef calves in North Dakota. North Dakota Beef Report. 2014;40-42.
⁷ Data on file, Study Report No. 3131R-60-08-548, Zoetis Inc.
⁸ Data on file, Study Report No. 3131R-60-09-720, Zoetis Inc.
⁹ Data on file, Study Report No. 3131R-60-08-568, Zoetis Inc.